Compare Gartner Inc (IT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Gartner Inc trades at $191.96 (market cap $12.34B), while State Street SPDR S&P Biotech ETF trades at $152.16 (market cap $10.11B). The key difference: Gartner Inc is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| IT | XBI | |
|---|---|---|
Market Cap | $12.34B | $10.11B |
Volume | 919,809 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $258.17 | $169.55 |
52-Week Low | $125.68 | $104.99 |
Typical Hold Time | 64 Days | 37 Days |
Enterprise Value | $14.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $195.09, up 5.02% today, showing strong momentum with three consecutive quarterly EPS beats. The stock exhibits bullish technical signals with support at $185 and resistance at $188. Fundamentally, the company maintains robust profitability with 69.63% gross margins and 12% net income margin, though 2025 net income declined to $729M from 2024's $1.3B. Recent news highlights AI advisory demand growth and the upcoming Gartner IT Symposium in October.
Outlook remains positive with analyst consensus at Buy (28%) and $174.63 price target, though current price exceeds target. Key opportunities include strong ROE (113.58%) and AI-driven consulting demand. Risks include negative cash flow trends (-$211M in 2025) and potential fiduciary investigation noted in recent filings. Institutional sentiment appears mixed with 56% Hold ratings.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
